Clinical study on transcatheter arterial chemoembolization and AIDI injection in treatment of primary hepatocellular carcinoma

OBJECTIVE To evaluate the efficacy of Aidi injection combined with transcatheter arterial chemoembolization in patients with primary hepatic carcinoma.METHODS The patients with primary hepatic carcinoma(n = 94)were random1y divided into two groups.Patients(n = 47)were treated with intravenous Aidi injection(100 ml in 500 ml 0.9%Nacl)for 28 days(dl-d28),and combined with transcatheter arterial chemoembolization(HCPT 10 mg,5-Fu 500 mg and iodinate oil 10 ml)for 28 days,according to Seldingers technique.The controls(n = 47)were treated with transcatheter arterial chemoembolization alone;after 2 circles of 28-day treatment,the therapeutic effects were evaluated.RESULTS In Aidi and control groups,the effective rates were 78.7% and 44.7%;the median survival time was 8.41 and 8.17 months,the mean survival time was 12.71 and 9.23 months,the half-a-year survival rate was 89.3% and 82.9%,one-year survival rate was 63.8% and 46.8%,and two-year survival rate was 27.7% and 17.0% respectively.For the initial patients in the two groups,the half-a-year survival rate was 83.1%,one-year survival rate was 47.7%,two-year survival rate was 18.5%;for the retreated patients,the corresponding rates were 96.3%,77.8% and 33.3%.After AFP treatment,the declined rate was 70.2% in 26 patients of Aidi group,and was 51.5% in 17 patients of control group.CONCLUSION Aidi injection can enhance the effects of transcatheter arterial chemoembolization,and improve the life quality of the patients and prolong the survival time in patients with primary hepatic carcinoma.The efficacy can be improved after repeated treatment.